Thanks.
Definitely all these bits and pieces of new products and services in the Pipeline in CSL R&D programme releases over next 2 to 3 years will have a game changing impact on valuation. Earliest bit of information I am waiting for is the update on merger status and confirmation of the benefits from Vifor acquisition. This should be fairly certain outcome IMO.
News: CSL Csl Behring Receives FDA Approval For Hizentra® (Immune Globulin Subcutaneous <Origin..., page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$255.31 |
Change
-2.070(0.80%) |
Mkt cap ! $123.6B | |||
| Open | High | Low | Value | Volume |
| $256.32 | $256.50 | $252.60 | $171.9M | 674.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6 | $255.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $255.83 | 104 | 1 |
View Market Depth
| Last trade - 16.14pm 21/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |